Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07473375
Recruiting Observational

Indicators Affecting PVT Recanalization

NCT07473375 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Zhongshan Hospital
Phase
Observational
Started
2017-01-01
Last updated
2026-03-16

Condition(s) studied

Portal Vein ThrombosisCirrhosisPortal Hypertension Related to CirrhosisPortal Hypertension, Noncirrhotic

Study summary

This is a retrospective-prospective study conducted at Zhongshan Hospital, Fudan University, to explore portal vein thrombosis (PVT) in patients with cirrhosis and gastroesophageal varices (GEV). It aimed to provide insights into the diagnosis, follow-up, and factors influencing PVT recanalization, to help patients, families, and healthcare providers understand the disease and related clinical management.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * diagnosed as cirrhosis and confirmed gastroesophageal varices by endoscopy; * all patients were diagnosed as PVT by CTA at admission. Exclusion Criteria: * patients with hepatocellular carcinoma; * patients with extrahepatic malignancies; * history of liver transplantation or TIPS; * lack of information regarding anticoagulation therapy； * those with cavernous transformation of the portal vein(CTPV) .

Primary outcome measure(s)

  • PVT recanalization at 1 year — From the first abdominal imaging assessment after admission, until the occurrence of PVT recanalization at 1 year, death, or the last follow-up, whichever came first

Trial sites (1)

FacilityCityRegionStatus
— Shanghai Shanghai Municipality Recruiting

More Shanghai Zhongshan Hospital trials in China

QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer Recruiting
ICCA-Based ICU Physiological State Space Monitor Active, not recruiting
Accelerated LBBP for Patients With RHF and Severe TR Starting soon
Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease Recruiting
Construction of a Portal Hypertension Biobank Recruiting

Other trials for the same condition

AI-guided TIPS Procedure Starting soon
Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection Recruiting
Effect of Laparoscopic Splenectomy on Lipid Profiles in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up) Starting soon
Preemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis Starting soon
Application of Bacterial DNA Quantitative Detection in Diagnosis of SBP in Cirrhosis: A Multi Center Diagnostic Experiment Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07473375 on ClinicalTrials.gov ↗ ← All trials in China